When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Netflix's new show The Abandons has a true cliffhanger ending, and we're here to break it down. One of the love stories of the season does get a (kind of) resolution. Did [SPOILER] and [SPOILER] ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
SPOILER ALERT: This story contains spoilers for the first two episodes of “Pluribus,” streaming now on Apple TV. Not only did “Breaking Bad” earn four more seasons that cemented it as one of the ...
The moves to fire or sideline generals and admirals are without precedent in recent decades and have rattled the top brass. Credit...Photographs by Andrew Caballero-Reynolds/Agence France-Presse — ...
Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...
Let's make this simple: You want to know if there are any post- or mid-credits scenes in Tron: Ares. The answer is yes, there is a mid-credits scene. That scene, along with the film’s “regular” final ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results